- Home
- BOOT vs SRRK Comparison
BOOT vs SRRK Comparison
Compare BOOT & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BOOT | SRRK |
|---|---|---|
| Founded | 1978 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 4.6B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BOOT | SRRK |
|---|---|---|
| Price | $204.81 | $44.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $203.67 | $47.00 |
| AVG Volume (30 Days) | 446.7K | ★ 2.1M |
| Earning Date | 01-29-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.30 | N/A |
| EPS | ★ 6.78 | N/A |
| Revenue | ★ $2,071,382,000.00 | N/A |
| Revenue This Year | $18.94 | N/A |
| Revenue Next Year | $13.11 | $20,271.77 |
| P/E Ratio | $30.18 | ★ N/A |
| Revenue Growth | ★ 17.82 | N/A |
| 52 Week Low | $86.17 | $22.71 |
| 52 Week High | $210.25 | $48.28 |
Technical Indicators
Market Signals| Indicator | BOOT | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 61.37 | 62.46 |
| Support Level | $196.35 | $43.92 |
| Resistance Level | $210.25 | $48.28 |
| Average True Range (ATR) | 6.86 | 2.17 |
| MACD | 1.11 | -0.01 |
| Stochastic Oscillator | 79.64 | 61.00 |
Price Performance
Historical ComparisonAbout BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.